INE232I01014
INE232I01014
SUN PHARMA ADV.RES.CO.LTD
Loading chart...
Company Profile
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Website
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
49.2% p.a.
Max Drawdown (5Y)
-76.1%
Sharpe Ratio (5Y)
-0.22
Beta Factor
0.65
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (49.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -84.0% in the extended horizon.